Subsequently, we analysed the survival outcome by decline of 5% Hb after NAC and demonstrated that patients with ≥ 5% Hb decline have an inferior DFS (mean 44.6 months), compared with those with < 5% Hb decline (63 months, p = 0.044, Fig. 1C), which was consistent with our previous finding that patients with severe post-NAC anemia had a worse outcome. The gene discussed is GSTM1; the disease is anemia (phenotype).